Literature DB >> 16242881

Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of ezetimibe in human plasma.

Shuijun Li1, Gangyi Liu, Jingying Jia, Xiaochuan Li, Chen Yu.   

Abstract

A simple, reliable and sensitive liquid chromatography-tandem mass spectrometry method (LC-MS/MS) was developed and validated for quantification of free and total ezetimibe in human plasma. The analyte and internal standard (13C6-ezetimibe) were extracted by liquid-liquid extraction with methyl tert-butyl ether. The reversed-phase chromatographic separation was performed on a Capcell C18 column, and the plasma extract was eluted with a gradient consisting of acetonitrile and 5 mM ammonium acetate. The analyte was detected using negative ionization by multiple reaction monitoring mode. The mass transition pairs of m/z 408.5-->270.8 and m/z 414.5-->276.8 were used to detect ezetimibe and internal standard, respectively. The assay exhibited linear ranges from 0.02 to 20 ng/ml for free ezetimibe and 0.25 to 250 ng/ml for total ezetimibe in human plasma. Acceptable precision and accuracy were obtained for concentrations of the calibration standard and quality control. The validated method was successfully used to analyze human plasma samples for application in a pharmacokinetic study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242881     DOI: 10.1016/j.jpba.2005.07.053

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.

Authors:  Jung-Woo Bae; Chang-Ik Choi; Jin-Hee Lee; Choon-Gon Jang; Myeon-Woo Chung; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2010-09-24       Impact factor: 2.953

2.  Metabolism and disposition of a novel antineoplastic JS-38 (Benzamide, N-[4-(2,4-dimethoxyphenyl)-4,5-dihydro-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl]-3,5-bis (trifluoromethyl)-(9Cl)) in rats.

Authors:  Hong Zhang; Quanhai Liu; Tingting Fan; Yu Fang; Ying Li; Guoping Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-07-30       Impact factor: 2.441

3.  Micelle-enhanced spectrofluorimetric method for determination of cholesterol-reducing drug ezetimibe in dosage forms.

Authors:  Nawal A Alarfaj; Fatma A Aly
Journal:  J Fluoresc       Date:  2011-08-23       Impact factor: 2.217

4.  Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects.

Authors:  Nan-Nan Chu; Wei-Li Chen; Hong-Rong Xu; Xue-Ning Li
Journal:  Clin Drug Investig       Date:  2012-12       Impact factor: 2.859

5.  Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe.

Authors:  Omar Patiño-Rodríguez; Irma Torres-Roque; Maricela Martínez-Delgado; Abraham Escobedo-Moratilla; José Pérez-Urizar
Journal:  Front Pharmacol       Date:  2014-11-27       Impact factor: 5.810

6.  Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study.

Authors:  Sireesha R Karanam; Prakash Katakam; Babu R Chandu; Nagiat T Hwisa; Shanta K Adiki
Journal:  J Pharm Anal       Date:  2013-08-16

7.  Current literature in mass spectrometry.

Authors: 
Journal:  J Mass Spectrom       Date:  2007-01       Impact factor: 1.982

8.  UV and Three Derivative Spectrophotometric Methods for Determination of Ezetimibe in Tablet Formulation.

Authors:  Metreyi Sharma; Deepali V Mhaske; M Mahadik; S S Kadam; S R Dhaneshwar
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

9.  Microemulsion liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe in their combined dosage forms.

Authors:  Mohammed E A Hammouda; Mohamed A Abu El-Enin; Dina T El-Sherbiny; Dalia R El-Wasseef; Saadia M El-Ashry
Journal:  J Anal Methods Chem       Date:  2013-10-27       Impact factor: 2.193

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.